Antibody array data showing activation of kinases in human red blood cells infected with the malaria parasite.
New research into malaria suggests targeting enzymes from the human host, rather than from the pathogen itself, could offer effective treatment for a range of infectious diseases, including COVID-19.
The study, conducted by an international team and led by RMIT University’s Professor Christian Doerig, outlines a strategy that could save years of drug discovery research and millions of dollars in drug development by repurposing existing treatments designed for other diseases such as cancer.
The approach shows so much promise it has received government funding for its potential application in the fight against COVID-19.
The study, published in Nature Communications, demonstrated that the parasites that cause malaria are heavily dependent on enzymes in red blood cells where the parasites hide and proliferate.
It also revealed that drugs developed for cancer, and which inactivate these human enzymes, known as protein kinases, are highly effective in killing the parasite and represent an alternative to drugs that target the parasite itself.
Lead author, RMIT’s Dr Jack Adderley, said the analysis revealed which of the host cell enzymes were activated during infection, revealing novel points of reliance of the parasite on its human host.
“This approach has the potential to considerably reduce the cost and accelerate the deployment of new and urgently needed antimalarials,” he said
“These host enzymes are in many instances the same as those activated in cancer cells, so we can now jump on the back of existing cancer drug discovery and look to repurpose a drug that is already available or close to completion of the drug development process.”
As well as enabling the repurposing of drugs, the approach is likely to reduce the emergence of drug resistance, as the pathogen cannot escape by simply mutating the target of the drug, as is the case for most currently available antimalarials.
Doerig, Associate Dean for the Biomedical Sciences Cluster at RMIT and senior author of the paper, said the findings were exciting, as drug resistance is one of the biggest challenges in modern healthcare, not only in the case of malaria, but with most infectious agents, including a large number of highly pathogenic bacterial species.
“We are at risk of returning to the pre-antibiotic era if we don’t solve this resistance problem, which constitutes a clear and present danger for global public health. We need innovative ways to address this issue,” he said.
“By targeting the host and not the pathogen itself, we remove the possibility for the pathogen to rapidly become resistant by mutating the target of the drug, as the target is made by the human host and not by the pathogen.”
Doerig’s team will now collaborate with the Peter Doherty Institute for Infection and Immunity (Doherty Institute) to investigate potential COVID-19 treatments using this approach, supported by funding from the Victorian Medical Research Acceleration Fund in partnership with the Bio Capital Impact Fund (BCIF).
Co-investigator on the grant, Royal Melbourne Hospital’s Dr Julian Druce, of the Victorian Infectious Diseases Reference Laboratory (VIDRL) at the Doherty Institute, was part of the team that were first to grow and share the virus that causes COVID-19, and said the research was an important contribution to efforts to defeat the pandemic.
Royal Melbourne Hospital’s Professor Peter Revill, Senior Medical Scientist at the Doherty Institute and a leader on Hepatitis B research, said the approach developed by the RMIT team was truly exciting.
“This has proven successful for other human pathogens including malaria and Hepatitis C virus, and there are now very real prospects to use it to discover novel drug targets for Hepatitis B and COVID-19,” he said.
The paper is the outcome of an RMIT-led international collaboration with researchers from Monash University in Melbourne, Dr Danny Wilson (University of Adelaide’s Malaria Biology Laboratory Head, The Hospital Research Foundation Fellow and Burnet Institute), Dr Jean-Philippe Semblat (from French Government agency Inserm, Paris) and Prof Oliver Billker (Umeå University, Sweden and Wellcome Sanger Institute, UK).
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Malaria discovery
- Malaria Infection Reduces In Borno
Borno State commissioner for Health and Human Resources, Prof Baba Gana has expressed delight that the rate of malaria infection is declining in the state.
- China helps Uganda fight malaria as global funding shrinks
For Milly Nakazzi, an assistant nursing officer at Uganda’s Kiruddu National Referral Hospital, the fact that at least six of every 10 patients she treats have malaria is business as usual. “The ...
- ‘Curse’ behind King Tutankhamun’s tomb mysterious deaths finally solved, experts claim
Egyptologist Arthur Weigall allegedly told colleagues that Carnarvon would “be dead within six weeks” upon entering, the study claimed.
- Burden Of Malaria In Nigeria
The global community is once again called to confront the reality that malaria remains a public health issue particularly in Africa.
- Experimental malaria monoclonal antibody protective in Malian children
One injected dose of an experimental malaria monoclonal antibody was 77% effective against malaria disease in children in Mali during the country's six-month malaria season, according to the results ...
Go deeper with Google Headlines on:
Malaria discovery
[google_news title=”” keyword=”malaria discovery” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Targeting host enzymes to fight disease
- Experts develop immune-enhancing therapies to target tuberculosis
Experts are working on novel immune-enhancing therapies called host-directed therapies to use the body's own immune system to target tuberculosis, with hopes that they could tackle even the ...
- Experts developing immune-enhancing therapies to target tuberculosis
Some immune-enhancing therapies already exist, and their use could be investigated while other immunomodulatory drugs specific to different sub-groups of TB disease are being developed Experts are ...
- Exploring the lung microbiome’s role in disease
Unusual microbial communities in a person’s lower airways could influence the onset and progression of lung cancer and other conditions, and might point the way to therapies.
- A promising target for new RNA therapeutics now accessible
Aberrant RNA methylation has been associated with cancers and other human diseases, making "writers" an attractive therapeutic target ... These molecules prevent the writer from absorbing the ...
- Drug Insight: Tumor Necrosis Factor Converting Enzyme as a Pharmaceutical Target for Rheumatoid Arthritis
One target for anti-TNF therapy that is currently under investigation is TNF-converting enzyme, which promotes the release of soluble TNF from its membrane-bound precursor. Inhibitors of this ...
Go deeper with Google Headlines on:
Targeting host enzymes to fight disease
[google_news title=”” keyword=”targeting host enzymes to fight disease” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]